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Background: Several novel biomarkers including markers of inflammation, hemostasis and homocysteine have established utility for prediction 
of future cardiovascular disease (CVD) events. We sought to explore gender disparities in prognostic utility of novel biomarkers to predict CVD and 
coronary heart disease (CHD) events in a multi-ethnic cohort of healthy US adults.
Methods: The study comprised 6814 asymptomatic men and women aged 45-84 years enrolled in the Multi-Ethnic Study of Atherosclerosis [MESA] 
study obtained from NHLBI data repository. A total of 5880 adults [3126 female and 2754 male] in whom a host of novel biomarkers drawn in the 
study were considered for this analysis. The events considered were ALL CVD events and ALL CHD events defined per MESA protocol. Multivariate Cox 
proportional-hazards modeling was used to adjust for demographic and other cardiovascular risk factors.
Results: We observed significant gender differences in the predictive value of novel biomarkers for cardiovascular risk assessment, in a large multi-
ethnic cohort of US adults free of clinical CVD. While C- reactive protein (CHD only) and D-Dimer emerged as predictors in females, Interleukin-6, 
homocysteine and fibrinogen were significant in males.(Table1)
Conclusion: Our findings underscore the need for a gender-specific approach in the utilization of biomarkers for cardiovascular risk stratification. 
Table 1. Multivariate Cox Proportional-Hazards Model for Gender Specific Utility of Novel Biomarkers in Predicting ALL CVD and ALL CHD Events. 
Bio-Marker Female (N= 3126) Male (N=2754)
ALL CVD* Events (N=102) ALL CHD** Events (N=59) ALL CVD* Events (N=175) ALL CHD* Events (N=137)
HR P value 95% CI HR P Value 95% CI HR P value 95% CI HR P Value 95% CI
IL-6 1.33 0.09 0.95- 1.86 1.04 0.8 0.67 - 1.63 1.47 0.002† 1.15 - 1.87 1.36 0.03† 1.03 - 1.79
CRP 1.19 0.06 0.98 - 1.44 1.31 0.03† 1.02 - 1.68 1.11 0.1 0.96 - 1.3 1.1 0.2 0.93 - 1.3
Homocysteine 1.47 0.2 0.8 - 2.72 2.01 0.06 0.95 - 4.25 2.49 <0.001† 1.56 - 3.98 2.27 0.003† 1.32 - 3.91
Fibrinogen 2.2 0.1 0.8 - 6.37 2.17 0.2 0.55 - 8.15 5.28 <0.001† 2.5 - 11.14 5.05 <0.001† 2.17 - 11.7
PAP 0.9 0.9 0.56 - 1.74 0.88 0.7 0.41 - 1.84 1.81 0.002 1.23 - 2.65 1.43 0.1 0.91 - 2.24
D-Dimer 1.32 0.01† 1.05 - 1.65 1.4 0.02† 1.05 - 1.86 1.16 0.07 0.98 - 1.37 1.14 0.1 0.94 - 1.38
Factor 8 1.0 0.07 0.99 - 1.01 1.0 0.06 0.99 - 1.01 1.0 0.2 0.99 - 1.01 1.0 0.1 0.99 - 1.01
*ALL CVD events : Myocardial infarction(MI), Resuscitated Cardiac Arrest (RCA), Definite Angina, Probable Angina (if followed by Revascularization), Stroke, Stroke Death, coronary heart 
disease (CHD) Death, Other Atherosclerotic Death, Other CVD Death.
** ALL CHD Events : MI, CHD Death, RCA.
CVD = Cardiovascular Disease, IL-6 = Interleukin-6, CRP= C Reactive Protein, PAP= Plasim-Antiplasmin Complex, HR = Hazard’s Ratio, CI = Confidence Interval.
† Bold print (table) -indicates statistical significance (p≤ 0.05).
Adjusted for Age, Race, Body Mass Index, History of smoking, Family history of CHD, Systolic blood pressure, Diabetes Mellitus, High Density Lipoprotein, Statin use and Total intentional 
exercise.
